Acute inhibition of hepatic β-oxidation in APOE*3Leiden mice does not affect hepatic VLDL secretion or insulin sensitivity

Journal of Lipid Research

Volumn 46, Issue 5, 2005, Pages 988-993

  Duivenvoorden, Ilse ^a,b   Teusink, Bas ^a,d   Rensen, Patrick C N ^a,b   Kuipers, Folkert ^c   Romijn, Johannes A ^b   Havekes, Louis M ^a,b   Voshol, Peter J ^a,b  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d NIZO FOOD RESEARCH   (Netherlands)

Author keywords

Fatty acids; Glucose metabolism; Steatosis; Triglycerides; Very low density lipoprotein

Indexed keywords

3 HYDROXYBUTYRATE DEHYDROGENASE; CARNITINE PALMITOYLTRANSFERASE INHIBITOR; CHOLESTEROL; INSULIN; PALMOXIRIC ACID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E3; APOLIPOPROTEIN E3 (LEIDEIN); FATTY ACID; MESSENGER RNA;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; FATTY ACID OXIDATION; GLUCONEOGENESIS; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; KETOGENESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; ANIMAL; BLOOD; GENETICS; INSULIN RESISTANCE; LIVER; METABOLISM; OXIDATION REDUCTION REACTION; PHYSIOLOGY; SECRETION;

ANIMALS; APOLIPOPROTEIN E3; APOLIPOPROTEINS E; FATTY ACIDS, NONESTERIFIED; INSULIN RESISTANCE; LIPOPROTEINS, VLDL; LIVER; MALE; MICE; MICE, TRANSGENIC; OXIDATION-REDUCTION; RNA, MESSENGER;

EID: 27244433830     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.M400505-JLR200     Document Type: Article

References (40)

1. Lewis, G. F. 1997. Fatty acid regulation of very low density lipoprotein production. Curr. Opin. Lipidol. 8: 146-153.
2. Randle, P. J., P. B. Garland, C. N. Hales, and E. A. Newsholme. 1963. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1: 785-789.
3. Shelness, G. S., and J. A. Sellers. 2001. Very-low-density lipoprotein assembly and secretion. Curr. Opin. Lipidol. 12: 151-157.
4. Kuipers, F., M. C. Jong, Y. Lin, M. Eck, R. Havinga, V. Bloks, H. J. Verkade, M. H. Hofker, H. Moshage, T. J. Berkel, et al. 1997. Impaired secretion of very low density lipoprotein-triglycerides by apolipoprotein E-deficient mouse hepatocytes. J. Clin. Invest. 100: 2915-2922.
5. Roe, C. R., and P. M. Coates. 1997. Mitochondrial fatty acid oxidation disorders. In The Metabolic and Molecular Bases of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill, New York. 1501-1533.
6. Schuler, A. M., and P. A. Wood. 2002. Mouse models for disorders of mitochondrial fatty acid beta-oxidation. ILAR J. 43: 57-65.
7. Eaton, S. 2002. Control of mitochondrial beta-oxidation flux. Prog. Lipid Res. 41: 197-239.
8. McGarry, J. D., and N. F. Brown. 1997. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur. J. Biochem. 244: 1-14.
9. Friedman, M. I., R. B. Harris, H. Ji, I. Ramirez, and M. G. Tordoff. 1999. Fatty acid oxidation affects food intake by altering hepatic energy status. Am. J. Physiol. 276: R1046-R1053.
10. Kiorpes, T. C., D. Hoerr, W. Ho, L. E. Weaner, M. G. Inman, and G. F. Tutwiler. 1984. Identification of 2-tetradecylglycidyl coenzyme A as the active form of methyl 2-tetradecylglycidate (methyl palmoxirate) and its characterization as an irreversible, active site-directed inhibitor of carnitine palmitoyltransferase A in isolated rat liver mitochondria. J. Biol. Chem. 259: 9750-9755.
11. van Vlijmen, B. J., A. M. van den Maagdenberg, M. J. Gijbels, H. van der Boom, H. HogenEsch, R. R. Frants, M. H. Hofker, and L. M. Havekes. 1994. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J. Clin. Invest. 93: 1403-1410.
12. van Vlijmen, B. J., H. B. van't Hof, M. J. Mol, H. van der Boom, A. van der Zee, R. R. Frants, M. H. Hofker, and L. M. Havekes. 1996. Modulation of very low density lipoprotein production and clearance contributes to age- and gender-dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice. J. Clin. Invest. 97: 1184-1192.
13. Mensenkamp, A. R., M. J. van Luyn, H. van Goor, V. Bloks, F. Apostel, J. Greeve, M. H. Hofker, M. C. Jong, B. J. van Vlijmen, L. M. Havekes, et al. 2000. Hepatic lipid accumulation, altered very low density lipoprotein formation and apolipoprotein E deposition in apolipoprotein E3-Leiden transgenic mice. J. Hepatol. 33: 189-198.
14. Mensenkamp, A. R., B. Teusink, J. F. Baller, H. Wolters, R. Havinga, K. W. van Dijk, L. M. Havekes, and F. Kuipers. 2001. Mice expressing only the mutant APOE3Leiden gene show impaired VLDL secretion. Arterioscler. Thromb. Vasc. Biol. 21: 1366-1372.
15. Zambon, A., S. I. Hashimoto, and J. D. Brunzell. 1993. Analysis of techniques to obtain plasma for measurement of levels of free fatty acids. J. Lipid Res. 34: 1021-1028.
16. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275.
17. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purification. Can. J. Med. Sci. 37: 911-917.
18. Havekes, L. M., E. C. de Wit, and H. M. Princen. 1987. Cellular free cholesterol in Hep G2 cells is only partially available for downregulation of low-density-lipoprotein receptor activity. Biochem. J. 247: 739-746.
19. Post, S. M., E. C. de Wit, and H. M. Princen. 1997. Cafestol, the cholesterol-raising factor in boiled coffee, suppresses bile acid synthesis by downregulation of cholesterol 7 alpha-hydroxylase and sterol 27-hydroxylase in rat hepatocytes. Arterioscler. Thromb. Vasc. Biol. 17: 3064-3070.
20. Aalto-Setala, K., E. A. Fisher, X. Chen, T. Chajek-Shaul, T. Hayek, R. Zechner, A. Walsh, R. Ramakrishnan, H. N. Ginsberg, and J. L. Breslow. 1992. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J. Clin. Invest. 90: 1889-1900.
21. Jong, M. C., V. E. Dahlmans, P. J. van Gorp, M. L. Breuer, M. J. Mol, A. van der Zee, R. R. Frants, M. H. Hofker, and L. M. Havekes. 1996. Both lipolysis and hepatic uptake of VLDL are impaired in transgenic mice coexpressing human apolipoprotein E*3Leiden and human apolipoprotein C1. Arterioscler. Thromb. Vasc. Biol. 16: 934-940.
22. Li, X., F. Catalina, S. M. Grundy, and S. Patel. 1996. Method to measure apolipoprotein B-48 and B-100 secretion rates in an individual mouse: evidence for a very rapid turnover of VLDL and preferential removal of B-48- relative to B-100-containing lipoproteins. J. Lipid Res. 37: 210-220.
23. Pietzsch, J., S. Subat, S. Nitzsche, W. Leonhardt, K. U. Schentke, and M. Hanefeld. 1995. Very fast ultracentrifugation of serum lipoproteins: influence on lipoprotein separation and composition. Biochim. Biophys. Acta. 1254: 77-88.
24. Koopmans, S. J., M. C. Jong, I. Que, V. E. Dahlmans, H. Pijl, J. K. Radder, M. Frolich, and L. M. Havekes. 2001. Hyperlipidaemia is associated with increased insulin-mediated glucose metabolism, reduced fatty acid metabolism and normal blood pressure in transgenic mice overexpressing human apolipoprotein C1. Diabetologia. 44: 437-443.
25. Voshol, P. J., M. C. Jong, V. E. Dahlmans, D. Kratky, S. Levak-Frank, R. Zechner, J. A. Romijn, and L. M. Havekes. 2001. In muscle-specific lipoprotein lipase-overexpressing mice, muscle triglyceride content is increased without inhibition of insulin-stimulated whole-body and muscle-specific glucose uptake. Diabetes. 50: 2585-2590.
26. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156-159.
27. Bloks, V. W., T. Plosch, H. van Goor, H. Roelofsen, J. Baller, R. Havinga, H. J. Verkade, A. van Tol, P. L. Jansen, and F. Kuipers. 2001. Hyperlipidemia and atherosclerosis associated with liver disease in ferrochelatase-deficient mice. J. Lipid Res. 42: 41-50.
28. Heid, C. A., J. Stevens, K. J. Livak, and P. M. Williams. 1996. Real time quantitative PCR. Genome Res. 6: 986-994.
29. Bandsma, R. H., T. H. Van Dijk, A. A. Harmsel, T. Kok, D. J. Reijngoud, B. Staels, and F. Kuipers. 2004. Hepatic de novo synthesis of glucose 6-phosphate is not affected in peroxisome proliferator-activated receptor alpha-deficient mice but is preferentially directed toward hepatic glycogen stores after a short term fast. J. Biol. Chem. 279: 8930-8937.
30. Post, S. M., M. Groenendijk, K. Solaas, P. C. Rensen, and H. M. Princen. 2004. Cholesterol 7alpha-hydroxylase deficiency in mice on an APOE*3-Leiden background impairs very-low-density lipoprotein production. Arterioscler. Thromb. Vasc. Biol. 24: 768-774.
31. Heijboer, A. C., E. Donga, P. J. Voshol, Z. C. Dang, L. M. Havekes, J. A. Romijn, and E. P. Corssmit. 2005. Sixteen hours fasting differentially affects hepatic and muscle insulin sensitivity in mice. J. Lipid Res. 46: 582-588.
32. den Boer, M., P. J. Voshol, F. Kuipers, L. M. Havekes, and J. A. Romijn. 2004. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler. Thromb. Vasc. Biol. 24: 644-649.
33. Foley, J. E. 1992. Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus. Diabetes Care. 15: 773-784.
34. Gonzalez-Manchon, C., M. S. Ayuso, and R. Parrilla. 1990. On the mechanism of sodium 2-5-4 chlorophenylpentyloxirane-2-carboxylate (POCA) inhibition of hepatic gluconeogenesis. Biochem. Pharmacol. 40: 1695-1699.
35. Mandarino, L., E. Tsalikian, S. Bartold, H. Marsh, A. Carney, E. Buerklin, G. Tutwiler, M. Haymond, B. Handwerger, and R. Rizza. 1984. Mechanism of hyperglycemia and response to treatment with an inhibitor of fatty acid oxidation in a patient with insulin resistance due to antiinsulin receptor antibodies. J. Clin. Endocrinol. Metab. 59: 658-664.
36. Tuman, R. W., G. F. Tutwiler, J. M. Joseph, and N. H. Wallace. 1988. Hypoglycaemic and hypoketonaemic effects of single and repeated oral doses of methyl palmoxirate (methyl 2-tetradecylglycidate) in streptozotocin/alloxan- induced diabetic dogs. Br. J. Pharmacol. 94: 130-136.
37. Boden, G., and X. Chen. 1999. Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes. Diabetes. 48: 577-583.
38. Jolly, R. A., R. Ciurlionis, D. Morfitt, M. Helgren, R. Patterson, R. G. Ulrich, and J. F. Waring. 2004. Microvesicular steatosis induced by a short chain fatty acid: effects on mitochondrial function and correlation with gene expression. Toxicol. Pathol. 32 (Suppl. 2): 19-25.
39. Horton, J. D., and I. Shimomura. 1999. Sterol regulatory element-binding proteins: activators of cholesterol and fatty acid biosynthesis. Curr. Opin. Lipidol. 10: 143-150.
40. Dobbins, R. L., L. S. Szczepaniak, B. Bentley, V. Esser, J. Myhill, and J. D. McGarry. 2001. Prolonged inhibition of muscle carnitine palmitoyltransferase-1 promotes intramyocellular lipid accumulation and insulin resistance in rats. Diabetes. 50: 123-130.